公开(公告)号：US20240199556A1

公开(公告)日：2024-06-20

申请号：US18225537

申请日：2023-07-24

申请人： G1 Therapeutics, Inc.

发明人： Stephen E. Schneider ,  Hannah White ,  Thomas Fessard ,  Sagar Beldar

IPC分类号： C07D241/38 ,  C07C219/18 ,  C07D239/47

CPC分类号： C07D241/38 ,  C07C219/18 ,  C07D239/47

摘要： This invention provides a process for preparing 1,4-diazaspiro[5.5]undecan-3-one and analogues thereof that are useful in the preparation of pharmaceutical compound, including for the treatment of disorders involving abnormal cellular proliferation. Chemical intermediates in the process are also provided.

公开(公告)号：US20230090256A1

公开(公告)日：2023-03-23

申请号：US17736895

申请日：2022-05-04

申请人： Cytokinetics, Inc.

发明人： Chihyuan CHUANG ,  Bradley P. MORGAN ,  Mark VANDERWAL ,  Luke W. ASHCRAFT ,  Kevin LAU

IPC分类号： C07D487/10 ,  C07D491/107 ,  C07D241/08 ,  C07D241/38 ,  C07D401/04 ,  C07D401/06 ,  C07D401/08 ,  C07D403/08 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/08 ,  C07D413/14 ,  C07D417/08 ,  A61P9/04

摘要： Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11427583B2

公开(公告)日：2022-08-30

申请号：US16591755

申请日：2019-10-03

申请人： WUHAN TIANMA MICROELECTRONICS CO., LTD. ,  WUHAN TIANMA MICROELECTRONICS CO., LTD. SHANGHAI BRANCH

发明人： Wenpeng Dai ,  Wei Gao ,  Lei Zhang ,  Jinghua Niu ,  Ying Liu ,  Ping An

IPC分类号： C07D209/82 ,  C07D221/06 ,  C07D221/18 ,  C07D241/38 ,  C07D265/34 ,  C07D279/14 ,  H01L51/00 ,  H01L51/50 ,  C07D471/06 ,  C07D405/14 ,  C07D409/14 ,  C07F7/08

摘要： The present disclosure relates to the field of organic electroluminescence materials and particularly relates to a compound, an OLED display panel and a display device. The compound according to the present disclosure has a structure represented by a formula (I) or a formula (II):

公开(公告)号：US11183643B2

公开(公告)日：2021-11-23

申请号：US16212292

申请日：2018-12-06

申请人： Shanghai Tianma AM-OLED Co., Ltd.

发明人： Lei Zhang ,  Xiangcheng Wang ,  Wei Gao ,  Jinghua Niu ,  Ying Liu ,  Gaojun Huang ,  Ping An ,  Xueqiang Luo

IPC分类号： H01L51/00 ,  C07D401/10 ,  C07D403/10 ,  C07D471/04 ,  C07D495/04 ,  C07D417/04 ,  C07D413/04 ,  C07D403/04 ,  C07D241/38 ,  C07D491/048 ,  H01L51/50

摘要： The present disclosure relates to a nitrogen heterocycle fused ring-indene compound having a structure represented by the Formula (I), in which Ar1 represents a substituted or unsubstituted aromatic fused ring group containing at least one nitrogen heteroaryl; Ar2 represents a chemical group acting as an electron donor; R1 and R2 are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C20 alkyl, substituted or unsubstituted C3-C20 cycloalkyl, substituted or unsubstituted C1-C20 alkoxy, substituted or unsubstituted C3-C20 heterocyclyl, substituted or unsubstituted C6-C40 aryl, and substituted or unsubstituted C5-C40 heteroaryl. The compounds according to the present disclosure have high glass transition temperature and thermal stability, and are easy to form a high-quality amorphous film, so that a driving voltage can be lowered, the luminous efficiency and lifetime of the device are improved.

公开(公告)号：US11154548B2

公开(公告)日：2021-10-26

申请号：US15769789

申请日：2016-10-21

申请人： Technical Institute of Physics and Chemistry of the Chinese Academy of Sciences

发明人： Pengfei Wang ,  Jiasheng Wu ,  Weimin Liu ,  Ying Gu ,  Jiechao Ge ,  Xiuli Zheng ,  Hongyan Zhang

IPC分类号： C07C217/12 ,  C07C221/00 ,  C07C225/22 ,  C07C225/32 ,  C07C229/18 ,  C07C237/08 ,  C07C239/14 ,  C07C243/22 ,  C07C249/02 ,  C07C251/24 ,  C07C251/56 ,  C07C251/86 ,  C07C309/69 ,  A61K31/122 ,  A61K31/135 ,  A61K31/473 ,  A61K41/00 ,  A61K47/54 ,  A61K47/60 ,  A61P35/00 ,  C07C323/25 ,  C07C319/18 ,  C07D279/14 ,  C07D487/08 ,  C07D513/06 ,  C07D513/16 ,  C07D241/38 ,  C07C50/36 ,  C07D221/02

摘要： The invention discloses a monosubstituted or polysubstituted amphiphilic hypocrellin derivative, and a preparation method and application thereof. The amphiphilic hypocrellin derivative substituted by a group containing PEG, a quaternary ammonium salt or the like prepared according to the invention has an obvious red shift in its absorption spectrum and a significantly enhanced molar extinction coefficient, compared with the parent hypocrellin, can efficiently produce singlet state oxygen and other reactive oxygen species under photosensitive conditions; has different amphiphilicities and increased biocompatibility with cells or tissues by regulating its hydrophilicity and hydrophobicity; can meet the requirements of different clinical drugs, and solves the requirements of different drug delivery methods for different drug hydrophilicity and lipophilicity. Under identical conditions, the amphiphilic hypocrellin derivative photosensitizer according to the invention has higher ability to photodynamically inactivate tumor cells than the first and second generation commercial photosensitizers.

公开(公告)号：US20210277014A1

公开(公告)日：2021-09-09

申请号：US17256142

申请日：2019-06-28

申请人： HISTOGEN, INC.

发明人： Alfred P. Spada ,  Robert J. Ternansky

IPC分类号： C07D491/048 ,  C07D401/06 ,  C07D241/08 ,  C07D403/12 ,  C07D409/06 ,  C07D403/06 ,  C07D405/06 ,  C07D409/12 ,  C07D471/04 ,  C07D241/38 ,  C07D241/04

摘要： The present invention relates to (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating e.g. cardiovascular, kidney, liver, lung, skin, joints, CNS, inflammatory and autoimmune diseases.

公开(公告)号：US20210111362A1

公开(公告)日：2021-04-15

申请号：US17127045

申请日：2020-12-18

申请人： Semiconductor Energy Laboratory Co., Ltd.

发明人： Satoshi Seo ,  Takeyoshi Watabe ,  Satomi Mitsumori

IPC分类号： H01L51/50 ,  C07D241/38 ,  C07D403/12 ,  C07D405/10 ,  C09K11/02 ,  C09K11/06 ,  H01L51/00

摘要： To provide a light-emitting element with high emission efficiency and low driving voltage. The light-emitting element includes a guest material and a host material. A LUMO level of the guest material is lower than a LUMO level of the host material. An energy difference between the LUMO level and a HOMO level of the guest material is larger than an energy difference between the LUMO level and a HOMO level of the host material. The guest material has a function of converting triplet excitation energy into light emission. An energy difference between the LUMO level of the guest material and the HOMO level of the host material is larger than or equal to energy of light emission of the guest material.

公开(公告)号：US20200181061A1

公开(公告)日：2020-06-11

申请号：US16784163

申请日：2020-02-06

申请人： FUJIFILM Corporation

发明人： Takafumi NAKAYAMA ,  Naoyuki MOROOKA

IPC分类号： C07C69/54 ,  C07D241/38 ,  C08F22/22 ,  C08F22/20 ,  G02B1/04

摘要： According to the present invention, as a monomer which is unlikely to be crystallized in a curable composition for manufacturing an optical member and which enables manufacture of a cured product having a high level of moisture-heat resistance, a compound represented by General Formula (A) is provided. In the formula, Ar11 and Ar12 each independently represent an aryl group or a heteroaryl group; X1, Y1, X2, Y2, Z1, and Z2 each independently represent a nitrogen atom or a carbon atom, or the like; Ar13 and Ar14 each independently represent an arylene group or a heteroarylene group, where at least one of Ar13 or Ar14 is a group other than a phenylene group; R3 to R6 each independently represent a substituent, q and r each independently are an integer of 0 to 4, and v and w each independently are an integer of 0 or more; L1 and L2 each independently represent a single bond, an oxygen atom, an ester bond, or the like; R11 and R12 each independently represent a divalent linking group containing a branched alkylene group; and R21 and R22 each independently represent a hydrogen atom or a methyl group.

公开(公告)号：US10669244B2

公开(公告)日：2020-06-02

申请号：US15887956

申请日：2018-02-02

申请人： President and Fellows of Harvard College

发明人： Andrew G. Myers ,  Mark G. Charest ,  Christian D. Lerner ,  Jason D. Brubaker ,  Dionicio R. Siegel

IPC分类号： C07C237/26 ,  C07D209/56 ,  C07D235/02 ,  C07D237/26 ,  C07D239/70 ,  C07D241/38 ,  C07D263/52 ,  C07D307/77 ,  C07D261/20 ,  C07D209/58 ,  C07D213/56 ,  C07D221/18 ,  C07D277/30 ,  C07D277/56 ,  C07D277/64 ,  C07D277/66 ,  C07C231/10

摘要： The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.

公开(公告)号：US10608185B2

公开(公告)日：2020-03-31

申请号：US15483032

申请日：2017-04-10

申请人： Universal Display Corporation

发明人： Chi Hang Lee ,  Raymond Kwong

IPC分类号： H01L51/00 ,  H01L51/50 ,  C09K11/06 ,  C09K11/02 ,  C07C13/62 ,  C07D409/14 ,  C07D403/04 ,  C07D409/10 ,  C07D493/04 ,  C07D491/147 ,  C07D407/10 ,  C07D497/04 ,  C07D221/18 ,  C07D411/14 ,  C07D401/04 ,  C07D403/14 ,  C07D241/38 ,  C07D471/04 ,  C07D403/10 ,  C07D498/04 ,  C07D411/04 ,  C07D471/14 ,  C07D209/86 ,  C07D413/04 ,  C07D409/04 ,  C07D401/14 ,  C07D405/04 ,  C07D405/14 ,  C07D497/14 ,  C07D311/78 ,  C07D265/34 ,  C07D307/91 ,  C07D413/14 ,  C07D491/052 ,  C07D498/14 ,  C07D327/06 ,  C07D491/048

摘要： The present invention includes fused tetraphenylene compounds that may be used as charge transporters, hosts or emitters in OLEDs.